13. Kim W, Cho MH, Sakornsakolpat P, Lynch DA, Coxson HO, Tal-Singer R, et al. DSP
variants may be associated with longitudinal change in quantitative emphysema. Respir Res …

Exacerbations have significant impact on the morbidity and mortality of patients with chronic
obstructive pulmonary disease. Most guidelines emphasise prevention of exacerbations by …

Long-acting inhaled bronchodilator medications are recommended as initial maintenance
therapy for many patients with COPD. These medications include long-acting muscarinic …

Treatment of acute exacerbations involves prompt administration of antibiotic therapy with
usually 14 days of oral, or for severe exacerbations, intravenous antibiotics. The role of …

Long‐acting bronchodilators and inhaled corticosteroids (ICS) are the cornerstones in
treatment of chronic obstructive and inflammatory pulmonary diseases. However, non …

BACKGROUND Chronic obstructive pulmonary disease (COPD) is the most common
smoking-related illness. COPD often is underemphasized as a comorbidity except when …

The purpose of this study was to systematically review the efficacy and safety of long-acting
β-agonist/long-acting muscarinic antagonist (LABA/LAMA) and LABA/inhaled corticosteroid …

Background: Pulmonary conditions such as asthma and chronic obstructive pulmonary
disease (COPD) are common conditions that warrant special consideration in the …

Exacerbations, which often lead to emergency department visits and hospitalizations, are
the main drivers of morbidity and utilization of health care resources among patients with …

Approximately 12 million adults in the United States receive a diagnosis of chronic
obstructive pulmonary disease (COPD) each year, and it is the fourth leading cause of …